[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

DZ2510A1 - Composition comprenant de la 5-Ä4-Ä2-(n-méthyl-n-(2-pyridyl)amino)éthoxyÜbenzylÜthiazolidine-2,4-dione et procédé pour sa préparation. - Google Patents

Composition comprenant de la 5-Ä4-Ä2-(n-méthyl-n-(2-pyridyl)amino)éthoxyÜbenzylÜthiazolidine-2,4-dione et procédé pour sa préparation.

Info

Publication number
DZ2510A1
DZ2510A1 DZ980120A DZ980120A DZ2510A1 DZ 2510 A1 DZ2510 A1 DZ 2510A1 DZ 980120 A DZ980120 A DZ 980120A DZ 980120 A DZ980120 A DZ 980120A DZ 2510 A1 DZ2510 A1 DZ 2510A1
Authority
DZ
Algeria
Prior art keywords
ethoxyübenzylüthiazolidine
dione
pyridyl
amino
methyl
Prior art date
Application number
DZ980120A
Other languages
English (en)
Inventor
Jai Patel
Hamish Ross
Jeffrey Roger Granett
Robin Price
Nigel Wray
Original Assignee
Smithkline Beecham Corp
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9712851.6A external-priority patent/GB9712851D0/en
Application filed by Smithkline Beecham Corp, Smithkline Beecham Plc filed Critical Smithkline Beecham Corp
Application granted granted Critical
Publication of DZ2510A1 publication Critical patent/DZ2510A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
DZ980120A 1997-06-05 1998-06-03 Composition comprenant de la 5-Ä4-Ä2-(n-méthyl-n-(2-pyridyl)amino)éthoxyÜbenzylÜthiazolidine-2,4-dione et procédé pour sa préparation. DZ2510A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9711683.4A GB9711683D0 (en) 1997-06-05 1997-06-05 Composition
GBGB9712851.6A GB9712851D0 (en) 1997-06-18 1997-06-18 Composition

Publications (1)

Publication Number Publication Date
DZ2510A1 true DZ2510A1 (fr) 2003-01-25

Family

ID=26311662

Family Applications (1)

Application Number Title Priority Date Filing Date
DZ980120A DZ2510A1 (fr) 1997-06-05 1998-06-03 Composition comprenant de la 5-Ä4-Ä2-(n-méthyl-n-(2-pyridyl)amino)éthoxyÜbenzylÜthiazolidine-2,4-dione et procédé pour sa préparation.

Country Status (29)

Country Link
EP (1) EP0998284A1 (fr)
JP (1) JP2001521553A (fr)
KR (1) KR20010013410A (fr)
CN (3) CN1112926C (fr)
AP (1) AP1214A (fr)
AR (2) AR008198A1 (fr)
AU (1) AU8215098A (fr)
BG (1) BG104048A (fr)
BR (1) BR9810405A (fr)
CA (2) CA2292629C (fr)
CO (1) CO4940400A1 (fr)
DZ (1) DZ2510A1 (fr)
EA (1) EA002384B1 (fr)
GB (1) GB9711683D0 (fr)
HU (1) HUP0004070A3 (fr)
ID (1) ID24264A (fr)
IL (1) IL133074A0 (fr)
MX (1) MXPA99011322A (fr)
NO (2) NO995938L (fr)
NZ (2) NZ523725A (fr)
OA (1) OA11306A (fr)
PE (1) PE78899A1 (fr)
PL (1) PL337201A1 (fr)
SK (1) SK164899A3 (fr)
TR (2) TR200002790T2 (fr)
TW (1) TW570797B (fr)
UY (1) UY25032A1 (fr)
WO (1) WO1998055122A1 (fr)
ZA (2) ZA9811572B (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ20013800A3 (cs) * 1999-04-23 2002-04-17 Smithkline Beecham Plc Polymorf soli 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]-benzyl]thiazolidin-2,4-dionu s kyselinou maleinovou
DE60004658T2 (de) 1999-04-23 2004-06-24 Smithkline Beecham Plc, Brentford Thiazolidindionderivat und seine verwendung als antidiabetikum
US20040248945A1 (en) 1999-04-23 2004-12-09 Smithkline Beecham P.L.C. Thiazolidinedione derivative and its use as antidiabetic
GB0021978D0 (en) 2000-09-07 2000-10-25 Smithkline Beecham Plc Novel pharmaceutical
GB0127805D0 (en) * 2001-11-20 2002-01-09 Smithkline Beecham Plc Pharmaceutical composition
GB0129876D0 (en) * 2001-12-13 2002-02-06 Smithkline Beecham Plc Novel pharmaceutical
WO2003050112A1 (fr) * 2001-12-13 2003-06-19 Smithkline Beecham Plc Hydrates de toluenesulfonate d'un derive de thiazolidinedione
GB0129871D0 (en) * 2001-12-13 2002-02-06 Smithkline Beecham Plc Novel pharmaceutical
GB0130509D0 (en) * 2001-12-20 2002-02-06 Smithkline Beecham Plc Novel pharmaceutical
US7435741B2 (en) 2006-05-09 2008-10-14 Teva Pharmaceutical Industries, Ltd. 2-N{5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2,4-thiazolidinedione} butanedioic acid, methods of preparation and compositions with rosiglitazone maleate
DE06252444T8 (de) * 2006-05-09 2009-03-19 Teva Pharmaceutical Industries Ltd. 2-N-{5-[[4-[2-(Methyl-2-pyridinylamino)-ethoxy]-phenyl]-methyl]-2,4-thiazolidindion}-bernsteinsäure, Verfahren zur Herstellung und Zusammensetzungen mit Rosiglitazonmaleat
WO2015008234A1 (fr) * 2013-07-17 2015-01-22 Glenmark Pharmaceuticals S.A. Composés hétécycliques bicycliques utilisés en tant que modulateurs des ror-gamma

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE186724T1 (de) * 1987-09-04 1999-12-15 Beecham Group Plc Substituierte thiazolidindionderivate
GB9218830D0 (en) * 1992-09-05 1992-10-21 Smithkline Beecham Plc Novel compounds
CN1083715C (zh) * 1994-02-10 2002-05-01 史密丝克莱恩比彻姆有限公司 胰岛素敏化物治疗肾病的应用
NZ313874A (en) * 1995-08-10 2000-09-29 Warner Lambert Co Compounds used as medicaments useful in eliminating the amount of exogenous insulin administered to a patient having noninsulin-dependent diabetes mellitus
WO1997018811A1 (fr) * 1995-11-17 1997-05-29 Warner-Lambert Company Procede de traitement de dystrophie myotonique
IL120443A (en) * 1996-03-18 2000-07-16 Sankyo Co Use of an insulin sensitizer for the manufacture of a medicament for the treatment or prophylaxis of pancreatitis
CN1230114A (zh) * 1996-07-12 1999-09-29 史密丝克莱恩比彻姆有限公司 Leptine抵抗的新疗法

Also Published As

Publication number Publication date
CA2292629C (fr) 2004-01-06
TW570797B (en) 2004-01-11
PE78899A1 (es) 1999-10-22
AR015120A1 (es) 2001-04-18
ZA984826B (en) 1999-08-03
TR200002790T2 (tr) 2001-11-21
WO1998055122A1 (fr) 1998-12-10
CN1259050A (zh) 2000-07-05
MXPA99011322A (es) 2004-12-02
GB9711683D0 (en) 1997-08-06
NZ513922A (en) 2001-09-28
NZ523725A (en) 2004-09-24
CA2292629A1 (fr) 1998-12-10
EA199901116A1 (ru) 2000-06-26
TR199902963T2 (xx) 2000-02-21
CN1526391A (zh) 2004-09-08
IL133074A0 (en) 2001-03-19
ZA9811572B (en) 1999-07-22
NO995938L (no) 2000-02-02
SK164899A3 (en) 2000-11-07
CN1112926C (zh) 2003-07-02
JP2001521553A (ja) 2001-11-06
CA2333352A1 (fr) 1998-12-10
HUP0004070A3 (en) 2002-03-28
NO995938D0 (no) 1999-12-03
AP9901696A0 (en) 1999-12-31
NO20040738L (no) 2000-02-02
BG104048A (bg) 2000-07-31
CN1430959A (zh) 2003-07-23
CO4940400A1 (es) 2000-07-24
EP0998284A1 (fr) 2000-05-10
KR20010013410A (fr) 2001-02-26
AR008198A1 (es) 1999-12-29
UY25032A1 (es) 1998-11-26
BR9810405A (pt) 2000-08-29
HUP0004070A2 (hu) 2002-02-28
PL337201A1 (en) 2000-08-14
OA11306A (en) 2003-10-22
AP1214A (en) 2003-10-08
ID24264A (id) 2000-07-13
EA002384B1 (ru) 2002-04-25
AU8215098A (en) 1998-12-21

Similar Documents

Publication Publication Date Title
DZ2457A1 (fr) Derivés de nicotinamide nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant.
HUP0004024A3 (en) Azabenzimidazole-based compounds, process for their preparation and pharmaceutical composition thereof
EE05214B1 (et) Polool-IFN- β konjugaat, selle valmistamismeetod ja farmatseutiline kompositsioon
DZ2172A1 (fr) Dérivés de triazole utiles on thérapeutique, procédé pour leur préparation et compositions les contenant.
AU7640696A (en) Thiazolidinedione derivatives, method for preparing the derivatives and pharmaceutical compositions containing same
CY2369B1 (en) Substituted heterocyclic compounds, preparation method therefor and pharmaceutical compositions containing same.
ZA9811759B (en) Novel indole derivatives, processes for their preparation, their use and pharmaceutical compositions containing them.
DZ2197A1 (fr) Dérivés de 6-phénylpyridyl-2-amine, procédé pour leur préparation et compositions pharmaceutiques les contenant.
HUP0100243A3 (en) Insoluble compositions comprising insuline and/or insuline-analogs and their derivatives, process for preparation thereof and their use for controlling blood glucose
HUP9801357A3 (en) Imidazoline-, imidazole-, oxazoline and thiazoline derivatives, pharmaceutical compositions containing them and process for producing them
DZ2114A1 (fr) Procédé pour la préparation du d-tartrate de (-)-cis-6(s)-phényl-5}4-(2-pyrrolidine-1-ylethoxy)-phénylÜ-5,6,7,8-tétrahydronaphtalène-2-ol.
DZ2074A1 (fr) Formulation nouvelle contenant de la paroxétine, et procédé pour sa préparation.
DZ3079A1 (fr) Procédé pour la préparation de 4-carboxy-amino-2-substitué-1,2,3,4 tétrahydroquinolé.
CH689805A8 (fr) Méthanesulfonate de paroxétine, procédé pour sa préparation et compositions pharmaceutiques le contenant.
ZA985406B (en) Pyrimidine-2,4,6-trione derivatives, processes for their production and pharmaceutical preparations containing these compounds.
IL136425A0 (en) Substituted thiazolidinedione derivative, process for its preparation and its pharmaceutical use
DZ2188A1 (fr) Dérivés de quinoxalinedone, procédés et intermédiaires pour leur préparation et compositions pharmaceutiques les contenant.
ZA974984B (en) New substituted thiazolidine-2,4-dione derivatives, processes for the obtaining thereof, and pharmaceutical compositions containing them.
DZ2510A1 (fr) Composition comprenant de la 5-Ä4-Ä2-(n-méthyl-n-(2-pyridyl)amino)éthoxyÜbenzylÜthiazolidine-2,4-dione et procédé pour sa préparation.
FR2791059B1 (fr) Proteine modifiee, procede de preparation de celle-ci et compositions pour une application externe contenant la proteine modifiee
DZ2641A1 (fr) Nouveaux procédés pour la préparation d'oméprazole.
CU22890A3 (es) Nuevo proceso de preparacion de derivados de fenilimidazolidina.
ZA9810033B (en) Process for the preparation of Thiazolidinedione Derivatives.
DK0838469T3 (da) 10,13,15-trioxatricyclo(9.2.1 9.6)-pentadecanon-derivater, fremgangsmåde til deres fremstilling og lægemidler indeholdende disse forbindelser
HUP0001551A3 (en) Improved method for producing thiazolidinediones, thiazolidinediones and pharmaceutical compositions containing the same